SAN DIEGO--(EON: Enhanced Online News)--Batu Biologics, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today the publication of mechanistic data for the ValloVax platform in the current issue of Oncotarget. The Company’s lead therapeutic, ValloVax, is a therapeutic vaccine designed to treat a wide array of solid tumors by targeting several pathways critical for tumor blood vessel formation, or angiogenesis. The current series of experiments sought to establish a basic understanding of the mechanism of action of the immune therapy, which will serve as the foundation for future clinical development.
“Our Company’s goal is to develop a patient-tailored treatment protocol that incorporates ValloVax alongside some of the best immunotherapeutic approaches to develop a curative approach for dealing with this terrible disease.”
Data in this manuscript demonstrates that ValloVax induces cellular and antibody immune responses in mouse models that are specific to targets found expressed on the tumor blood vessels. Furthermore, this publication explores the functionality Batu Biologics proprietary pretreatment process to the ValloVax cells, which acts as a “built in” adjuvant potentiating a Th1 type immune response. In mouse models, combination with a PD-1 or CTLA-4 blockade resulted in the complete remission of pre-existing tumors, illuminating the potential for a combination clinical study in the future.
“A detailed understanding of the in vivo mechanism of action for the ValloVax mediated immune response helps elucidate the specificity of the therapeutic,” commented Dr. Thomas Ichim, Chief Scientific Officer of Batu Biologics. “The data in this publication demonstrates the potential for ValloVax to induce a powerful anti-tumor response against the tumor blood vessels without damaging healthy vasculature in the body.”
Co-authors and collaborators for the publication include Dr. Santosh Kesari, Director of Neuro-Oncology at the John Wayne Cancer Institute, Dr. Amit N. Patel, Chief of Cardiac Surgery at the University of Miami Health System, and Dr. Wei-ping Min, Professor, Department of Immunology, University of Western Ontario.
“The results of this study clearly illustrate the potential of ValloVax for efficacy in the treatment of solid tumors regardless of tissue origin,” stated Samuel C. Wagner, President and CEO of Batu Biologics. “Our Company’s goal is to develop a patient-tailored treatment protocol that incorporates ValloVax alongside some of the best immunotherapeutic approaches to develop a curative approach for dealing with this terrible disease.”